AGIO Overview

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.

Wall Street analysts forecast AGIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGIO is36.14 USD with a low forecast of 25.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Agios Pharmaceuticals Inc revenue for the last quarter amounts to 19.97M USD, increased 86.09

Agios Pharmaceuticals Inc. EPS for the last quarter amounts to -1.85 USD, increased 9.47

Agios Pharmaceuticals Inc (AGIO) has 539 emplpoyees as of March 12 2026.

Today AGIO has the market capitalization of 1.64B USD.